Format

Send to

Choose Destination
See comment in PubMed Commons below
Trop Med Int Health. 2009 Jan;14(1):88-92. doi: 10.1111/j.1365-3156.2008.02195.x. Epub 2008 Dec 11.

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.

Author information

1
UNICEF/UNDP/WB/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland. olliarop@who.int

Abstract

OBJECTIVE AND METHOD:

To estimate drug costs of treating visceral leishmaniasis (VL) based on data on the VL population structure from the high-burden, antimony-resistant area of Northern Bihar, India.

RESULTS:

Paromomycin is the cheapest option ($7450 to treat 1000 patients). Treating 1000 patients with oral miltefosine would cost $119,250 at the current private market price or $64,383-$75,129 at preferential public sector price depending on the size of the order. With AmBisome it would be $163,600 or $229,500 depending on the dose (10 or 15 mg/kg total). These costs are without considering other direct costs (daily intramuscular injections for 3 weeks for paromomycin; intravenous devices and hospitalization for AmBisome; directly observed treatment if applied for miltefosine) and indirect costs.

CONCLUSION:

These calculations provide useful basic information for projections.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center